Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban

59Citations
Citations of this article
161Readers
Mendeley users who have this article in their library.

Abstract

The new oral anticoagulants dabigatran etexilate (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) have predictable pharmacokinetic and pharmacodynamic profiles and are alternatives to warfarin. However, many physicians are wary of these drugs, since there is limited evidence on how to manage bleeding in patients taking them, and since no specific antidote is known to reverse their anticoagulant effect. Management requires careful adherence to first principles of bleeding care. Unapproved and untested reversal strategies may be required in patients with life-threatening bleeding.

Cite

CITATION STYLE

APA

Fawole, A., Daw, H. A., & Crowther, M. A. (2013). Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleveland Clinic Journal of Medicine, 80(7), 443–451. https://doi.org/10.3949/ccjm.80a.13025

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free